Nolvadex and clomiphene citrate ( Lopezite) are two distinct classes of fertility medications. Nolvadex, which also goes by the names Xenical, Desmopressin and Clomid, is a medication used to treat males with a sperm-DNA abnormality. The most common male sperm disorders are testicular germ cell defects, low sperm mobility or limited motility. The second most common cause for male infertility is hypogonadism, where there is an imbalance in the testes. Clomiphene citrate (Lopezite), a synthetic version of the natural hormone testosterone, acts to stimulate testosterone production in men who suffer from blocked fallopian tubes, leading to impaired fertility.
There have been relatively few cases of Nolvadex and clomiphen citrate (related to bone pain, urinary tract infections and prostate cancer) side effects reported to date. However, these rare events may be related to preparation and dosage, both of which may have been underestimated by some supplement companies. Unfortunately, there is one very common side effect associated with nolvadex and clomiphen citrate (unintentional weight loss) that is virtually unknown with most other medications. Weight loss is a known side effect of nolvadex and clomiphen citrate, and there are other medications available that can help you lose weight.
One of the most common Nolvadex side effects is breast cancer. Some women who took high dosages of nolvadex for chemotherapy reported developing breast cancer; however, this was attributed to some of the cancer drugs that were being used at the time. In studies of patients taking tamoxifen, an estrogen suppression drug, the incidence of breast cancer was found to be lower in those women who had already begun using tamoxifen. However, since estrogen is not the only factor involved in breast cancer, it is unclear why women who were not taking tamoxifen saw reduced risk of developing Nolvadex breast cancer when using nolvadex. This is one of the few Nolvadex-related breast cancer incidents noted.
Another possible side effect of the combination of nolvadex and tamoxifen citrate was sexual dysfunction. Women who took the highest recommended dosages of nolvadex reported having less sex than women in the placebo group. No conclusions can be made regarding the safety of this sexual decline in women with sexual dysfunction due to Tamoxifen. However, there were fewer subjects in the placebo group with decreased sex drive than in the group with tamoxifen citrate. This lack of data may mean that other factors, such as depression, affect sexual performance after menopause.
Another side effect of nolvadex was a slight increase in body temperature. Again, this could be attributed to the placebo effect. However, there were fewer of the subjects reporting hot flashes and fewer of them had significant elevation in body temperature. This might not be significant enough to establish a definite link between the two medications, but the observation is suggestive of an unexplained finding. A limitation of the study by dermatologists is that although there were more females in the placebo group than in the nolvadex group, there was no statistical difference in the proportion of female patients with hot flashes, which are known to be associated with the onset of the menopause.
One of the most common side effects of treatment with nolvadex was joint pain and stiffness. Again, there was a greater number of female patients in the tamoxifen group receiving nolvadex than in the placebo group, but the difference in pain and stiffness was not significant. Patients with osteoporosis were also more likely to be prescribed nolvadex. It is not clear from the data how nolvadex affects bone pain in patients with osteoporosis. More research is needed to confirm this finding and the effect of nolvadex on bone pain.